Trading update

Ideagen plc

(''Ideagen'' or the ''Company'')

Trading update, Maiden Dividend and Notice of Results

Ideagen (AIM: IDEA), a leading supplier of Compliance based Information Management Software, issues the following update for the six month period to 31 October 2013.

Trading Update

Trading during the six month period continues to be robust with revenues and adjusted EBITDA* expected to show significant growth over the same period last year.

Revenues and adjusted EBITDA* have increased significantly due to the acquisitions of Plumtree and MSS combined with strong underlying organic growth**.

Furthermore, the Balance Sheet remains robust with a strong cash balance, which provides the Company with the financial platform to make further complementary acquisitions.

The Company continues to trade in-line with market expectations for the full year to 30 April 2014.

Maiden Dividend

Due to the continued success of the business and confidence in the future, the Board is now in a position to recommend the implementation of a progressive dividend policy which will comprise of an interim and final dividend. The board therefore intends to declare a maiden interim dividend of 0.05p per ordinary share at the time of announcing the Company's interim results. Full details of the record date and payment date of the interim dividend, once it is declared, will be announced with the Company's interim results.

Notice of Results

The interim results for the six months ended 31 October 2013 will be announced on January 14th 2014.

David Hornsby, Chief Executive Officer, commented:

"The Company has produced further growth in the period and is trading in line with expectations at the half year point. I am particularly pleased with our performance in the UK Health Sector which is benefiting from the dismantlement of the National Programme for IT (NpfIT) and the Government's strategic focus on a ''Paperless NHS'' by 2018. I am also delighted to announce our intention to pay the Company's maiden dividend which is a reflection of our confidence in current and future trading.''

*earnings before interest, tax, depreciation, amortization, share based payments and acquisition costs.

** organic revenue growth on a pro-forma basis excluding revenues generated in either period from the US Department of Veterans Affairs 'Prism' contract.